Ellagic Acid medical references (continued)
Ellagic Acid is known to inhibit certain carcinogen-induced cancers and may have other chemo preventive properties. The effects of ellagic acid on cell cycle events and apoptosis were studied in cervical carcinoma (CaSki) cells. We found that ellagic acid at a concentration of 10(-5) M induced G arrest within 48 hours, inhibited overall cell growth and induced apoptosis in CaSki cells after 72 hours of treatment. Activation of the cdk inhibitory protein p21 by ellagic acid suggests a role for ellagic acid in cell cycle regulation of cancer cells.
Narayanan BA, Geoffroy O, Willingham MC, Re GG, Nixon DW - Hollings Cancer Center, Medical University of South Carolina, Charleston 29425.
Ellagic Acid efficacy to inhibit lung tumorigenesis induced by NNK. The sales-weighted average of NNK deliveries from Canadian cigarettes was 73.2 ng/cigarette. NNK deliveries were highly correlated to declared tar values and were linear with puff volumes between 20 and 50 ml. Ellagic acid inhibited lung tumorigenesis induced by NNK in A/J mice. This inhibition was related to the logarithm of the dose of ellagic acid added to the diet. The biodistribution of ellagic acid was studied in mice gavaged with ellagic acid. Pulmonary levels of ellagic acid were directly proportional to the dose of ellagic acid between 0.2 and 2.0 mmol/kg b.w.
Castonguay A - Laboratory of Cancer Etiology and Chemoprevention, School of Pharmacy, Laval University, Quebec City, Canada.
Protective effects of 14 kinds of antioxidant on liver injury induced by carbon tetrachloride (CCl4) were investigated in terms of serum enzyme activities and bilirubin concentration. Consequently, the significant protective effects were found in sesamol, ellagic acid, cysteamine and cysteine. These antioxidants clearly decreased the lipid peroxide in the liver tissue. The protective effects on CCl4-induced liver injury in vivo were independent of the inhibitory activities on lipid peroxidation in hepatic mitochondria fraction in vitro.
Ohta S, Kamogawa A, Shinoda M - Faculty of Pharmaceutical Science, Hoshi University, Tokyo, Japan.
Ellagic acid elicits a dose-dependent bactericidal effect in H. pylori cultures, the bacteria thought primarily responsible for the development of gastric ulcers (Chung).
Ellagic acid is an effective inhibitor of lung and esophageal tumors in mice (Stoner). Ellagic acid inhibits lipid peroxide and liver hydroxy proline and rectifies liver pathology in laboratory animal hepatotoxcity induced by carbon tetrachloride (Thresiamma).
Cancer can affect DNA by covalent bonding of the carcinogen to the DNA molecule. Ellagic acid inhibits mutagenesis and carcinogenesis by forming adducts with DNA, thus masking binding sites to be occupied by the mutagen or carcinogen (Teel).
Ellagic acid treatment of preweanling mice before an injection of B(a)P diol-epoxide caused a 44-75% inhibition in the number of diol-epoxide-induced lung tumors (Chang).
Ellagic acid inhibits N-nitrosomethylbenzylamine (NMBA) tumorigenesis in the oesophagus of F-344 rats. Ellagic acid inhibited the development of both preneoplastic and neoplastic lesions by 25-50% (Daniel and Stoner).
Ellagic acid reduced the number of altered foci and the incidence of hepatocellular neoplasms in rats with liver cancer induced by N-2-fluorenylacetamide (Tanaka).
Ellagic acid inhibits lipid peroxidation necrosis of skin flaps, enhancing preservation of grafting procedures (Ashoori).
Ellagic acid has a marked inhibitory effect on acid secretion and the occurrence of stress-induced gastric lesions (Murakami).
